# Study to Assess the Effects and Safety of ZGN-1061 in Overweight and Obese Participants With Type 2 Diabetes

Study · id `cardio:ct-nct03254368` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03254368](<https://clinicaltrials.gov/study/NCT03254368>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03254368

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 188 participants.

## Technical summary

Registry record NCT03254368. Randomized; quadruple masking; primary purpose treatment. Start 2017-09-12 (actual); primary completion 2018-11-12 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 188 participants (enrolled count; ClinicalTrials.gov record NCT03254368, source copy `cardio:ctgov-nct03254368-2019-05-24`, retrieved 2026-10-26)
- Started: 2017-09-12 (actual) (ClinicalTrials.gov record NCT03254368, source copy `cardio:ctgov-nct03254368-2019-05-24`, retrieved 2026-10-26)
- Primary completion: 2018-11-12 (actual) (ClinicalTrials.gov record NCT03254368, source copy `cardio:ctgov-nct03254368-2019-05-24`, retrieved 2026-10-26)
- Completion: 2019-02-22 (actual) (ClinicalTrials.gov record NCT03254368, source copy `cardio:ctgov-nct03254368-2019-05-24`, retrieved 2026-10-26)
- Countries: Australia; New Zealand (ClinicalTrials.gov record NCT03254368, source copy `cardio:ctgov-nct03254368-2019-05-24`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03254368-2019-05-24`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study to Assess the Effects and Safety of ZGN-1061 in Overweight and Obese Participants With Type 2 Diabetes
- Condition: Type 2 Diabetes Mellitus
- Condition: Overweight and Obesity
- Intervention (Drug): ZGN-1061
- Intervention (Drug): Placebo
- Lead sponsor: Zafgen, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: 25ecfd10b61a2a0438447b5008464ae84dcd41f2b129deea74203b43f3f76762
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
